Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.89 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.89 |
| ▸ | PGR | P06401 | 2/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.89 |
| ▸ | SHBG | P04278 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL3098606 | 1.00 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL2678895 | 1.00 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL42272 | 1.00 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL8584044 | 0.97 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL250127 | 0.95 | HIF1A (0.93) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL13046615 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL6370134 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL13202859 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL10292969 | 0.94 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529904-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110269699-A1 | CANCER THERAPY | PETER MACCALLUM CANCER CENTRE (AU) | 2011-11-03 | — | — | US | claimed |
| EP-2309854-A1 | ACCELERATED THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| US-20120046442-A1 | ROMIDEPSIN SOLID FORMS AND USES THEREOF | APTUIT, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110269699-A1 | CANCER THERAPY | PETER MACCALLUM CANCER CENTRE (AU) | 2011-11-03 | — | — | US | disclosed |
| EP-2381964-A1 | SYNTHESIS OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS | Creabilis S.a. (LU) | 2011-11-02 | — | — | EP | disclosed |
| EP-2309854-A1 | ACCELERATED THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20050208602-A1 | 89 human secreted proteins | HUMAN GENOME SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| US-20040146893-A1 | Nucleotide sequences coding heterologous polypeptide for use in diagnosis and treatment of nervous system, cell proliferative, inflammatory and autoimmune diseases; wound healing agents | HUMAN GENOME SCIENCES, INC. (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046442-A1 | ROMIDEPSIN SOLID FORMS AND USES THEREOF | RDX, RPLP1, SFPQ | NR3C1 3092/4885HIF1A 4546/4885HSD17B10 2480/4885 |
| US-20110269699-A1 | CANCER THERAPY | BCL3, BCL2, BCL2L2 | NR3C1 1252/4885HIF1A 1989/4885HSD17B10 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.